Director/PDMR Shareholding

RNS Number : 3112Z
Dechra Pharmaceuticals PLC
05 March 2013
 



 

 

 

5 March 2013

 

Dechra Pharmaceuticals PLC

(the "Company")

Director / PDMR Shareholding

 

 

The Company announces that the following Directors/PDMRs were today granted nil cost options over ordinary shares of 1 pence each in the Company in connection with the Dechra Long Term Incentive Plan 2008 (the "Plan"):

 

Name of individual

Director/PDMR

Type of award

Number of shares subject to award

Ian Page

Director

Option

94,420

Tony Griffin

Director

Option

34,401

Ed Torr

Director

Option

32,838

Zoe Goulding

PDMR

Option

17,167

 

 

The vesting of all the above awards is subject to the achievement of performance targets.  In respect of these grants the performance conditions will be determined by reference to the Company's Earnings per Share ("EPS") and its Total Shareholder Return ("TSR") relative to constituent companies of the FTSE 250 index (excluding investment trusts) over a three year performance period.  Both the EPS and TSR elements will be subject to an additional Return on Capital Employed ("ROCE") performance measure.  If the ROCE performance condition is not met, then the LTIP options will lapse in full.

 

For further information, please contact:

 

Zoe Goulding, Company Secretary            

Telephone number: 01782 771100

 

 

About Dechra

Dechra is an international veterinary pharmaceutical business.  Its expertise is in the development, manufacturing, distribution, sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information please visit: www.dechra.com

 

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSNKPDPABKDBNK
UK 100

Latest directors dealings